| Title |
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
|
|---|---|
| Published in |
BioDrugs, May 2013
|
| DOI | 10.1007/s40259-013-0036-3 |
| Pubmed ID | |
| Authors |
Jan Visser, Isabel Feuerstein, Thomas Stangler, Timo Schmiederer, Cornelius Fritsch, Martin Schiestl |
| Abstract |
Regulatory approval for a biosimilar product is provided on the basis of its comparability to an originator product. A thorough physicochemical and functional comparability exercise is a key element in demonstrating biosimilarity. Here we report the characterization of a proposed biosimilar rituximab (GP2013) and originator rituximab. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 240 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| Hungary | 1 | <1% |
| Brazil | 1 | <1% |
| Switzerland | 1 | <1% |
| China | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 233 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 76 | 32% |
| Student > Ph. D. Student | 32 | 13% |
| Student > Master | 30 | 13% |
| Other | 24 | 10% |
| Student > Bachelor | 18 | 8% |
| Other | 24 | 10% |
| Unknown | 36 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 60 | 25% |
| Biochemistry, Genetics and Molecular Biology | 37 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 33 | 14% |
| Chemistry | 20 | 8% |
| Medicine and Dentistry | 18 | 8% |
| Other | 24 | 10% |
| Unknown | 48 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 August 2018.
All research outputs
#2,096,088
of 22,741,406 outputs
Outputs from BioDrugs
#43
of 646 outputs
Outputs of similar age
#18,595
of 193,579 outputs
Outputs of similar age from BioDrugs
#3
of 19 outputs
Altmetric has tracked 22,741,406 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 646 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,579 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.